Chronic Cough News

In a trial evaluating a refractory chronic cough treatment, continuous cough monitoring allowed researchers access to an abundance of data and the treatment’s impact over time, according to a presentation at the Hyfe Cough Science Forum.

WASHINGTON — Patients with asthma face heightened odds for chronic cough, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

The FDA has issued a complete response letter declining to approve a new drug application for gefapixant as a treatment for adults with refractory or unexplained chronic cough, according to a press release from Merck.

In November, all but one of the members of the FDA’s Pulmonary-Allergy Drugs Advisory Committee voted against recommending the approval of gefapixant for adults with refractory or unexplained chronic cough.

In a 12-to-1 vote, the FDA’s Pulmonary-Allergy Drug Advisory Committee voted against approving gefapixant 45 mg tablets to treat adults with refractory or unexplained chronic cough.

Gefapixant only showed small effects vs. placebo on objective cough frequency, cough severity and quality of life among adults with refractory or unexplained chronic cough, according to results of a systematic review and meta-analysis.

PARK CITY, Utah — Chronic cough has a variety of causes in children, with broad options for treatment, according to a talk at the Association of PAs in Allergy, Asthma and Immunology Annual Allergy, Asthma & Immunology CME Conference.

Current treatments for chronic cough fail to effectively resolve its symptoms, indicating a need to develop new therapies, according to the results of a survey of allergy specialists published in Annals of Allergy, Asthma & Immunology.

Worse cough-specific quality of life appears to be associated with risk for respiratory hospitalization, death and lung transplantation in patients with interstitial lung disease, researchers reported in Chest.